8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 21, 2026·SEC
Material company update
May 1, 2026·SEC
Coeptis Therapeutics, Inc.(COEP)Earnings, Financials & Key Ratios
COEP•NASDAQ
$12.44
Price updated Jun 27, 2026
AboutCoeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.Show more
- Revenue$1M
- EBITDA-$12M-31.1%
- Net Income-$12M-11.6%
- EPS (Diluted)-2.81+50.3%
- Gross Margin86.75%
- EBITDA Margin-867.24%
- Operating Margin-956.94%
- Net Margin-874.29%
- ROE-110.23%+57.8%
COEP Price & Volume
Coeptis Therapeutics, Inc. (COEP) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Mask Clinical Development Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Coeptis Therapeutics remains a high-risk, clinical-stage entity characterized by erratic revenue streams and a structural reliance on external financing to sustain its GEAR platform. While the company has managed to maintain a current ratio of 3.25 as of 2026Q1, the accumulation of -$113.9M in retained earnings highlights a long-term trend of shareholder value erosion. Investors should monitor the company's ability to transition from milestone-driven revenue to a sustainable commercial model, as current operating margins of -34.4% suggest significant ongoing capital requirements."
Verdict Logic
the company's reliance on dilutive financing to cover persistent quarterly cash burns of up to $2.4M suggests significant downside risk for long-term equity holders.
COEP Growth Metrics
Coeptis Therapeutics, Inc. (COEP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years113.45%
3 Years-
TTM2148.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-183.07%
Return on Capital
10 Years-355.67%
5 Years-355.67%
3 Years-241.78%
Last Year-116.11%
Peers Comparison
Key metrics vs top competitors for Coeptis Therapeutics, Inc. (COEP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.44 | $43.71M | -4.43 | — | -874.29% | -110.23% | — | |
| $2.36 | $259.66K | -0.25 | — | -227.72% | -25.53% | — | |
| $5.65 | $1.96B | -9.42 | 698.96% | -102.06% | -44.1% | — | |
| $4.70 | $190.82M | 3.85 | 36.55% | -19.55% | -3.39% | — | |
| $3.92 | $281.16M | 11.88 | -31.8% | 21.61% | 10.62% | — | |
| $15.91 | $330.93M | -8.84 | -6.55% | -15.64% | -7.34% | — |
Compare COEP vs Peers
Coeptis Therapeutics, Inc. (COEP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
COEP SEC Filings & Documents
Coeptis Therapeutics, Inc. (COEP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when COEP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
COEP Frequently Asked Questions
Coeptis Therapeutics, Inc. (COEP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Coeptis Therapeutics, Inc.'s revenue?
Coeptis Therapeutics, Inc. (COEP) reported $1.4M in revenue for fiscal year 2025.
Is COEP profitable?
Coeptis Therapeutics, Inc. (COEP) reported a net loss of $11.9M for fiscal year 2025.
Dividend & Returns
What is COEP's return on equity?
Coeptis Therapeutics, Inc. (COEP) has a return on equity (ROE) of -110.2%. Negative ROE indicates the company is unprofitable.
What is Coeptis Therapeutics, Inc.'s free cash flow?
Coeptis Therapeutics, Inc. (COEP) had negative free cash flow of $8.0M in fiscal year 2025, likely due to heavy capital investments.